Adventure sports: A study on safety issues in Rishikesh

Abstract Rishikesh, located in the Himalayan state of Uttarakhand, emerged as a prominent face of adventure tourism globally.Every year, thousands of enthusiastic tourists visit the city in search of exhilarating adventure. This paper focuses on the safetyissues in adventure sports in the region. The news of adventure turning into misadventure has increased in the recent past. Thedata has been collected through a personal visit to adventure city. The safety issues were personally witnessed that raised variousconcerns regarding the way adventure sports are conducted. The situation calls for strict laws to regulate the adventure activitiesin the region.

Research of improving intravenous therapy by using six Sigma methodology among inpatients / 中国实用护理杂志

Objective To explore the effect of improving the process of intravenous therapy using six Sigma methodology among hospitalized patients. Methods Select patients of a certain ward in our hospital as the objects. Used the steps of standard six Sigma methodology as define, measure, analyze, improve, and control. Analyze the relevant causes and formulate improvement measures after identifying and defining the adverse events. Quality control team ensured the implementation of the improvement measures, and finally compared the incidences of adverse events before and after the implementation of the measures. Results Before implementation of the improvement measures, intravenous therapy was performed within 1056 persons in a month. There were 132 adverse events, and the percentage was 12.5％. After the implementation of improvement measures, 1102 patients were performed intravenous therapy. There were 81 adverse events, and the percentage was 7.4％. The incidence of adverse events was significantly reduced (χ2=16.08, P<0.01). Conclusion The application of six Sigma management method can effectively improve the effect of intravenous treatment of inpatients with reducing the incidence of adverse events.

Cell-based technologies for Huntington's disease / Tecnologias celulares no doença de Huntington

ABSTRACT Huntington's disease (HD) is a fatal genetic disorder, which causes the progressive breakdown of neurons in the human brain. HD deteriorates human physical and mental abilities over time and has no cure. Stem cell-based technologies are promising novel treatments, and in HD, they aim to replace lost neurons and/or to prevent neural cell death. Herein we discuss the use of human fetal tissue (hFT), neural stem cells (NSCs) of hFT origin or embryonic stem cells (ESCs) and induced pluripotent stem cells (IPSCs), in clinical and pre-clinical studies. The in vivo use of mesenchymal stem cells (MSCs), which are derived from non-neural tissues, will also be discussed. All these studies prove the potential of stem cells for transplantation therapy in HD, demonstrating cell grafting and the ability to differentiate into mature neurons, resulting in behavioral improvements. We claim that there are still many problems to overcome before these technologies become available for HD patient treatment, such as: a) safety regarding the use of NSCs and pluripotent stem cells, which are potentially teratogenic; b) safety regarding the transplantation procedure itself, which represents a risk and needs to be better studied; and finally c) technical and ethical issues regarding cells of fetal and embryonic origin.

RESUMO A doença de Huntington (DH) é uma desordem genética que provoca a destruição progressiva dos neurônios no cérebro humano. A DH deteriora progressivamente as habilidades físicas e mentais humanas, e é incurável. Tecnologias terapêuticas baseadas em células representam novas alternativas para diversas doenças neurodegenerativas, pois visam substituir neurônios e/ou prevenir a morte neuronal. Nesta revisão discutirmos o uso de tecido fetal humano, células tronco neurais (CTN) de origem fetal ou de células tronco embrionárias ou células tronco pluripotentes induzidas, em estudos pré-clínicos e clínicos. Além disso, o uso terapêutico de células derivadas de tecidos não-neurais, como células tronco mesenquimais, também será discutido. Todos estes estudos provam o potencial do transplante celular na DH, demonstrando a sua habilidade em enxertar no encéfalo e diferenciar em neurônios in vivo, resultando em melhorias comportamentais e motoras em modelos animais da DH. Nós também discutimos que há muitos problemas a serem resolvidos quanto à terapia celular na DH, tais como: a) questões associadas à segurança do uso de CTNs, as quais são consideradas potencialmente teratogênicas; b) segurança do procedimento de transplante intracerebral, que representa um risco ao paciente; c) e, finalmente, questões técnicas e éticas associadas ao uso de células de origem fetal e embrionária.